Direct inhibition of PRRX1 transcriptional activity in mesenchymal cells may be a potential therapeutic target in IPF as supported by our encouraging results in Human IPF PCLS. This evidence concerns the gene PRRX1 and idiopathic pulmonary fibrosis.